Please login to the form below

Not currently logged in

Armando Anido appointed CEO of NuPathe

Will lead company as it develops single-use migraine patch

Former Auxilium Pharmaceuticals president and CEO Armando Anido has been appointed as the new CEO of US biopharma NuPathe.

Anido replaces NuPathe's founder Jane Hollingsworth who has resigned from the position two years after being named Ernst & Young's Entrepreneur of the Year.

At the forefront of Anido's tasks will be to lead the company as it develops lead product candidate NP1010 – a single-use transdermal patch for the treatment of migraine.

In addition, NuPathe has two products in development that make use of its long-acting delivery technology that allows delivery of therapeutic levels of medication over a period of months with a single dose.

These comprise NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202, for the long-term treatment of schizophrenia and bipolar disorder.

Anido has more than 30 years' experience in senior biopharma positions, including his five years in charge of Auxilium. Under his leadership, sales grew from $42m in 2005 to more than $260m in 2011.

Prior to this role, Anido served as executive VP, sales and marketing, at MedImmune and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories.

His time at GlaxoWellcome involved responsibility for the commercialisation of the migraine, epilepsy and depression businesses in the US, setting Anido up well for NuPathe.

"NuPathe has developed a highly innovative and differentiated product for the treatment of migraine," said Anido. "This product innovation, combined with a large population of underserved migraine patients and an outstanding commercial team, builds the foundation required for a successful launch.”

26th July 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...